Moderna, Inc. (MRNA) /

The cash flow of Moderna, Inc. over the past 10 years

Chart Moderna, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →

In fiscal 2025, the latest fiscal year on file, Moderna, Inc.'s operating cash flow was -$1.87B and its capital expenditures $192M, leaving free cash flow of -$2.06B. Free cash flow was above zero in 4 of the 10 years shown. It ranged from -$4.05B in fiscal 2024 to $13.34B in fiscal 2021. Capital expenditures were highest in fiscal 2024, at $1.05B.

Year by year

Fiscal yearOperating cash flowCapital expendituresFree cash flow*
2025ended Dec 31, 2025-$1.87B$192M-$2.06B
2024ended Dec 31, 2024-$3B$1.05B-$4.05B
2023ended Dec 31, 2023-$3.12B$707M-$3.83B
2022ended Dec 31, 2022$4.98B$400M$4.58B
2021ended Dec 31, 2021$13.62B$284M$13.34B
2020ended Dec 31, 2020$2.03B$68M$1.96B
2019ended Dec 31, 2019-$459M$32M-$491M
2018ended Dec 31, 2018-$330.87M$105.77M-$436.63M
2017ended Dec 31, 2017-$331.48M$58.4M-$389.88M
2016ended Dec 31, 2016$66.73M$33.14M$33.59M

Fiscal years as Moderna, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.

More on Moderna, Inc.

Companies of a similar size

Not investment advice. This page shows what Moderna, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.